Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chemours will discontinue U.S. sales of these select Freon products as of May 2, 2024, in support of regulatory phasedown requi...
Consolidated Adjusted EBITDA also to be up approximately 15% compared with first quarter 2024 results.
Chemours (NYSE:CC) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.18 by 77.78 p...
Chemours (NYSE:CC) reported quarterly sales of $1.350 billion which beat the analyst consensus estimate of $1.349 billion by 0....
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often com...
Chemours Co (NYSE: CC) reported in late March its fourth-quarter earnings ahead of expectations.
BMO Capital analyst John McNulty upgrades Chemours (NYSE:CC) from Market Perform to Outperform and raises the price target f...
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and raises the price target from $21 to $28.
